CNS Clinical Trials

87 recruitingLast updated: May 13, 2026

There are 87 actively recruiting cns clinical trials across 32 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Paris, France, Seoul, South Korea. Updated daily from ClinicalTrials.gov.


CNS Trials at a Glance

87 actively recruiting trials for cns are listed on ClinicalTrialsFinder across 6 cities in 32 countries. The largest study group is Phase 2 with 30 trials, with the heaviest enrollment activity in New York, Paris, and Seoul. Lead sponsors running cns studies include Memorial Sloan Kettering Cancer Center, Children's National Research Institute, and Ruijin Hospital.

Treatments under study

About CNS Clinical Trials

Looking for clinical trials for CNS? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new CNS trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about CNS clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 87 trials

Recruiting
Phase 1Phase 2

[90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients

CNS Lymphoma
Pentixapharm AG15 enrolled2 locationsNCT06132737
Recruiting
Phase 1

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Primary Central Nervous System LymphomaCentral Nervous System LymphomaSecondary Central Nervous System Lymphoma+4 more
Memorial Sloan Kettering Cancer Center26 enrolled8 locationsNCT07082868
Recruiting
Phase 1Phase 2

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

ALK Fusion-positive Solid or CNS Tumors
Hoffmann-La Roche42 enrolled33 locationsNCT04774718
Recruiting
Not Applicable

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

MelanomaBreast Cancer, NOSCNS Primary Tumor, NOS+9 more
Eastern Cooperative Oncology Group400 enrolled347 locationsNCT05108298
Recruiting
Phase 1

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Solid TumorLymphomaGIST+5 more
ITM Solucin GmbH20 enrolled5 locationsNCT06441331
Recruiting
Early Phase 1

A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.

PineoblastomaMedulloblastoma RecurrentHigh-Grade Gliomas+4 more
Children's National Research Institute18 enrolled1 locationNCT07017816
Recruiting
Phase 1Phase 2

Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma

CNS MetastasesB-cell Lymphoma RecurrentB-cell Lymphoma Refractory
Samsung Medical Center37 enrolled2 locationsNCT06552559
Recruiting
Phase 2

Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.

Primary CNS Lymphoma
Kim, Seok Jin30 enrolled1 locationNCT04627753
Recruiting
Phase 1Phase 2

Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

GliomaCNS Tumor, AdultCNS Tumor, Childhood
Centre Leon Berard70 enrolled11 locationsNCT07243470
Recruiting
Phase 2

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

CNS TumorHigh Grade Glioma
St. Jude Children's Research Hospital52 enrolled4 locationsNCT06528691
Recruiting

Characterizing Sleep Among Long-term Survivors of Childhood Cancer

Solid TumorALL, AdultCNS Tumor
St. Jude Children's Research Hospital120 enrolled1 locationNCT05480904
Recruiting
Phase 1

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

Secondary Central Nervous System LymphomaPrimary Central Nervous System (CNS) Lymphoma
Memorial Sloan Kettering Cancer Center12 enrolled7 locationsNCT07137494
Recruiting
Phase 1

A Study of PHST001 in Advanced Solid Tumors

Ovarian CancerEndometrial CancerCholangiocarcinoma+2 more
Pheast Therapeutics272 enrolled20 locationsNCT06840886
Recruiting
Phase 3

A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions

For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
Shanghai Shengdi Pharmaceutical Co., Ltd250 enrolled2 locationsNCT07275814
Recruiting
Phase 2Phase 3

A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients

Known or Highly Suspected Central Nervous System (CNS) LesionKnown or Highly Suspected Body (Excluding CNS) Lesion
GE Healthcare640 enrolled1 locationNCT07472491
Recruiting
Phase 2

Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)Primary Central Nervous System Lymphoma (PCNSL)
Beijing Tongren Hospital43 enrolled1 locationNCT07523737
Recruiting
Phase 1

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled48 locationsNCT06253871
Recruiting
Not Applicable

Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors

Breast CancerProstate CancerHead and Neck Cancer+4 more
The New York Proton Center1,800 enrolled1 locationNCT05313191
Recruiting
Not Applicable

Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors

Brain CancerGliomasRecurrent CNS Tumors+3 more
National Cancer Institute (NCI)80 enrolled1 locationNCT07374692